Citations

Clear

9383 citation(s) found for "Thomas, PS".

Abstract DP020: Quantification of Hematoma and Perihematomal Edema Volumes in Intracerebral Hemorrhage The QUANTUM Randomized Clinical Trial
Ironside, Natasha , Patrie, James, Kumar, Jeyan S. , Naamani, Kareem El, Abbas, Rawad , Becerril, Andrea Pecina, Chen, Ching-Jen, Rizvi, Tanvir , Mastorakos, Panagiotis , Naamani, Kareem El , Snyder, M. Harrison

Mayo Clinic

Stroke | January 29, 2026 | Volume: 57 | Issue: Suppl_1 | Pages: No page available

10.1161/str.57.suppl_1.dp020 Get It

Introduction: Optimizing patient selection and time-to-intervention will be crucial to the success of future clinical trials seeking to implement therapies and improve intracerebral hemorrhage (ICH) patient outcomes. Automated and accurate ICH and perihematomal edema (PHE) volumetry carries significant potential to strengthen trials targeting ICH and PHE expansion. Aims: The Quantification of Hematoma and Perihematomal Edema Volumes in Intracerebral Hemorrhage (QUANTUM) trial was designed with aims of (1) validating a fully automated artificial intelligence (AI) method for supratentorial, spontaneous ICH and PHE volumetry against the manual and semiautomated quantification methods and (2) establishing a model framework for the translation of AI technology through conduct of a clinical trial under the equivalence hypothesis paradigm. Methods: This trial was a prospective, randomized, clinical study with blinded outcome assessment. Six independent raters were randomized in a 1:1 ratio to ICH and PHE volumetry from non-contrast CT scans in the Virtual International Stroke Trials Archive with either the semiautomated or manual quantification method. The primary outcomes were equivalence between (1)ICH volume measurements on admission (<24h from symptom onset) for the manual versus the fully automated or the sem-automated quantification methods, and (2)PHE volume measurements on day 3 (72±12h from symptom onset) for the manual versus the fully automated or the semiautomated quantification methods. The required sample size was 126 ICH and 126 PHE measurements, based upon a significance level of 0.025 to account for the two equivalence tests. Results: The geometric mean relative discrepancies between the fully automated and the manual ICH and PHE volume measurements did not cross the pre-specified 10% equivalence margin. The geometric mean relative discrepancies between the semiautomated and the manual ICH and PHE volume measurements did cross the pre-specified 10% equivalence margin. The fully automated method (mean 10.0±2.7s/scan) was significantly faster than the manual (mean 189±199 s/scan; P <0.001) and semiautomated (mean 79±68s/scan; P <0.001) methods. Conclusions: ICH and PHE volumes quantified by AI could replace clinician measurements within a 10% error margin and with substantially greater efficiency. The semiautomated method could not replace manual measurements. This trial demonstrated feasibility of the equivalence hypothesis framework for AI validation studies.
Abstract A034: Outcomes of Patent Foramen Ovale Closure in Patients Over 60 Years with Cryptogenic Stroke: A Systematic Review and Meta-Analysis
Phan, Cattien , Ghozy, Sherief, Ravichandran, Soumya , Maleki, Ana H., Dumitrascu, Oana, Agrawal, Kush , Modir, Royya , Hemmen, Thomas, Poli, Sven, Zuern, Christine S., Trabattoni, Daniela, Meyer, Brett C. , Jazayeri, Seyed Behnam , Ghozy, Sherief , Hemmen, Thomas , Poli, Sven , Zuern, Christine S. , Trabattoni, Daniela , Meyer, Dawn , Shahripour, Reza Bavarsad

Mayo Clinic

Stroke | January 29, 2026 | Volume: 57 | Issue: Suppl_1 | Pages: No page available

10.1161/str.57.suppl_1.a034 Get It

Background: In younger patients (<60 years) with cryptogenic stroke presumed to be patent foramen ovale (PFO)-related, the standard approach involves transcatheter PFO closure combined with antithrombotic therapy (ATA). However, due to their exclusion from randomized clinical trials, no formal recommendations exist for patients ≥60 years. This study investigates whether PFO closure benefits patients ≥60 years with prior cryptogenic stroke or if ATA remains the preferred option. Methods: We searched the PubMed, Embase, Web of Science, and ScienceDirect databases to obtain articles in all languages from January 2004 until July 2025. The primary outcome was a risk of recurrent stroke during follow-up and secondary outcomes were risk of new-onset atrial fibrillation (AF), all-cause mortality and in-hospital complications. PROSPERO registration ID: CRD420250652870. Results: One post hoc evaluation of the DEFENSE-PFO trial and eleven observational studies were included. Compared to ATA, PFO closure was associated with a reduced risk of recurrent stroke (HR=0.60; 95% CI: 0.45 to 0.80, p<.001) and mortality (HR=0.41; 95% CI: 0.19 to 0.90, p=.02; I2 = 43.8%) with no difference in risk of new-onset AF (HR=1.13, 95%CI: 0.53 to 2.44, p=.74). When compared with patients <60 years, individuals ≥60 years had a higher risk of recurrent stroke (HR = 2.68; 95% CI 1.40–5.13; p=.002), new-onset AF (HR = 4.12; 95% CI 1.90–8.95; p<0.001) and mortality during follow-up (HR = 8.24; 95% CI 3.49–19.46; p<.0001). In-hospital complications after PFO closure were comparable between two age groups. Conclusion: While PFO closure may reduce ischemic stroke risk in older patients with cryptogenic stroke, this benefit is offset by higher absolute risks for recurrent stroke, new-onset AF, and mortality. Therefore, highly individualized patient selection and age-specific risk tools are crucial. Further long-term randomized trials are essential to optimize PFO closure in this population.
Abstract WP112: Predictors of 90-Day Recurrent Stroke in Patients with High-Grade Intracranial Atherosclerotic Stenosis: A subgroup analysis from the BIORISK-ICAS Study
Stretz, Christoph, Lewis, Skylar, Chahien, Dalia, Alam, Shaista , Halabi, Tarek El, Guerrero, Chris, Walsh, Hadley A., Frontera, Jennifer, baker, rich, Nguyen, Thanh, Tunguturi, Ajay, Khan, Muhib, Klaas, James P. , Liebeskind, D, Morsi, Rami, Helenius, Johanna, Khatri, Pooja, Freitas, Joao, Aziz, Yasmin, Rothstein, Aaron, Shu, Liqi , Reda, Mahasen, Tountopoulou, Argyro , Khasawneh, Mohammad W , Klein, Piers, Havenon, Adam de, Almiri, William , Prabhakaran, S, AlMajali, Mohammad, Zaidat, Osama, Qdais, Ahmad Abu, McCullough-Hicks, Margy, Elangovan, Cheran, Sousa, João André, Romoli, Michele, Henninger, Nils, Marto, Joao Pedro, Agarwal, Ayush, Kasab, Sami Al, Yaddanapudi, Sridhara , Krishnaiah, Balaji , Sousa, Diana Aguiar de, Yaghi, Shadi, Henninger, Nils , Sousa, Diana Aguiar de , Henninger, Nils , Aguiar de Sousa, Diana , Khan, Fahad , Stretz, Christoph , Alam, Shaista, Halabi, Tarek El , Sloane, Kelly L , Heldner, Mirjam R. , Antonenko, Kateryna , Baker, Richard, Khan, Muhib , Marrone, Nicole L. , Siegler, James E. , Morsi, Rami Z. , Aziz, Yasmin , Rothstein, Aaron , Reda, Mahasen , Prabhakaran, Shyam , McCullough‐Hicks, Margy , Elangovan, Cheran , Romoli, Michele , Marto, João Pedro , Kasab, Sami Al

Mayo Clinic

Stroke | January 29, 2026 | Volume: 57 | Issue: Suppl_1 | Pages: No page available

10.1161/str.57.suppl_1.wp112 Get It

Background: High-grade intracranial atherosclerosis (ICAS) is associated with an elevated risk of recurrent ischemic stroke, particularly in patients with severe stenosis (70–99%). Identifying predictors of early recurrence can inform risk stratification and guide treatment strategies. Methods: The Biomarkers and Recurrence Risk in Symptomatic Intracranial Arterial Stenosis (BIORISK-ICAS) study is a multicenter, international, retrospective cohort analysis pooling data from 35 comprehensive stroke centers. We included hospitalized adult patients with symptomatic ICAS, defined as 50–99% stenosis of an intracranial artery (intracranial vertebral, basilar, distal ICA, or M1 MCA), confirmed by vascular imaging and associated with a qualifying ischemic event. Patients with only high-grade stenosis (70-99%) were included in this analysis. The primary outcome was to determine predictors of recurrent ischemic stroke in the territory of the symptomatic artery within 90 days of the index event. Baseline demographic, clinical, and imaging characteristics were recorded. Multivariable Cox proportional hazards regression with stepwise selection (p < 0.1) was used to identify independent predictors of recurrence; model discrimination was assessed using Harrell’s C-statistics. Results: Among 2,050 patients, 1,476 had high-grade (70-99%) symptomatic ICAS. The mean age was 67 ± 12.5 years, and 767 (55%) were male. Most patients were non-Hispanic (90.1%), taking dual antiplatelet therapy (77.8%), and statins (94.5%). Recurrent stroke occurred in 160 patients (10.8%) within 90 days. In multivariable Cox model, independent predictors of recurrence included atrial fibrillation (HR 2.05; 95% CI, 1.26–3.33; p = 0.004), hyperlipidemia (HR 1.57; 95% CI, 1.10–2.24; p = 0.014), diabetes mellitus (HR 1.36; 95% CI, 0.98–1.88; p = 0.064), and home use of dual antiplatelet therapy (HR 1.60; 95% CI, 1.01–2.54; p = 0.043)(Harrell’s C-statistic=0.62). In patients who underwent perfusion(n=402), mistmatch >10seconds were associated with increased recurrence (HR 1.80; 95% CI 0.95-3.38, p=0.07) and atrial fibrillation (HR 2.06: 95% CI 0.03-4.60, p=0.78) though did not reach statistical significance. Conclusion: In this population, diabetes, hyperlipidemia, atrial fibrillation, and prior use of dual antiplatelet therapy were associated with increased risk of 90-day recurrent ischemic stroke. Perfusion imaging may help identify high-risk patients who could benefit from intensified secondary prevention.
Abstract DP310: Dual Antiplatelet versus Anticoagulant-Plus-Antiplatelet Therapy in Symptomatic Intracranial Atherosclerosis: A Multicenter Comparative Study
Rehman, M. Aemaz Ur, Yaghi, Shadi, Kasab, Sami Al, Qdais, Ahmad Abu, Yaddanapudi, Sridhara , Sultana, Sabiha , Khan, Muhib, Malik, Maarij , Klaas, James P. , Guerrero, Christopher Leon, Velez, Faddi Saleh, Pinto, Camila, McCullough-Hicks, Margy, Cooper, Dawson C , Pillai, Abhiram Parameswaran, Hariharan, Praveen, Alam, Shaista , Antonenko, Kateryna, Almiri, William , Rothstein, Aaron, Krishnaiah, Balaji , Elangovan, Cheran, Agarwal, Ayush, Romoli, Michele, Nicola, Marrone, Vozzi, Stefano, Ghannam, Malik, Dibas, Mahmoud I., Marto, Joao Pedro, AlMajali, Mohammad, Sousa, Diana Aguiar de, Soares, Mafalda Delgado, Lima, Anicléia Rodrigues de, Tountopoulou, Argyro , Havenon, Adam de, Henninger, Nils, Helenius, Johanna, Khasawneh, Mohammad W , Klein, Piers, Shu, Liqi , Khatri, Pooja, Nguyen, Thanh N., Liebeskind, D, Bakradze, Ekaterina, Henninger, Nils , Sousa, Diana Aguiar de , Henninger, Nils , Aguiar de Sousa, Diana , Khan, Fahad , Yaghi, Shadi , Kasab, Sami Al , Sultana, Sabiha, Khan, Muhib , Leon Guerrero, Christopher R , Velez, Faddi G. Saleh , Owens, Cameron , Pinto, Camila, McCullough‐Hicks, Margy , Hariharan, Praveen , Alam, Shaista, Heldner, Mirjam R. , Antonenko, Kateryna , Rothstein, Aaron , Elangovan, Cheran , Romoli, Michele , Marrone, Nicola , Ghannam, Malik , Dibas, Mahmoud, Marto, João Pedro , Simpkins, Alexis N. , Soares, Mafalda , Lima, Amanda, Siegler, James E. , VASILOPOULOU, SOFIA, Klein, Piers , Bakradze, Ekaterina

Mayo Clinic

Stroke | January 29, 2026 | Volume: 57 | Issue: Suppl_1 | Pages: No page available

10.1161/str.57.suppl_1.dp310 Get It

Introduction: Intracranial atherosclerosis (ICAS) is a leading cause of ischemic stroke (IS) worldwide and carries a high risk of recurrence. Current guidelines favor 90 days of dual antiplatelet therapy (DAPT) for severe symptomatic ICAS, but recurrence remain high. Limited data suggest possible benefit of single antiplatelet plus anticoagulation (SAPT+AC). We compared the effectiveness and safety of DAPT versus SAPT+AC. We hypothesized that DAPT would lower 90-day recurrent IS risk without significantly increasing bleeding. Methods: This substudy of the Biomarkers and Recurrence Risk in Symptomatic Intracranial Arterial Stenosis (BIORISK-ICAS) included patients from 35 centers (Jan 2019–Jun 2024) with symptomatic 50–99% ICAS in the intracranial internal carotid, vertebral, basilar, or M1 segment of the MCA, presenting ≤72 hours from last known well. The primary efficacy outcome was recurrent IS in the same vascular territory at 90 days; the primary safety outcome was severe bleeding (symptomatic intracranial hemorrhage or major extracranial bleeding). Categorical variables were compared using χ 2 and continuous variables with the Student's t test; multivariable Cox regression adjusted for key covariates. Results: Of 2050 BIORISK-ICAS patients, 1658 met criteria (DAPT n=1499; SAPT+AC n=159). Mean age was 67 vs. 73 years, and 44% were women. At 90 days, recurrent IS occurred in 121 DAPT patients (8.07%) vs. 13 SAPT+AC patients (8.17%); unadjusted HR 0.83 (95% CI, 0.50–1.36; p=0.46). After adjustment for age, diabetes, coronary heart disease, atrial fibrillation, active smoking, and borderzone infarct, the adjusted HR was 0.99 (95% CI, 0.52–1.86; p=0.97). Severe bleeding occurred in 34 DAPT patients (2.26%) and 5 SAPT+AC patients (3.14%); unadjusted HR 0.79 (95% CI, 0.28–1.85; p=0.50), adjusted HR 0.66 (95% CI, 0.21–2.09; p=0.47). Conclusions: In patients with symptomatic ICAS, DAPT and SAPT+AC were associated with similar risks of 90-day recurrent ischemic stroke and severe bleeding. Well-powered randomized trials are needed to determine the optimal antithrombotic regimen in this high-risk population.
Relationship Between Degree of Stenosis and Time-to-Peak Delay in High Grade Asymptomatic Carotid Artery Disease
Marshall, Randolph S. , Lal, Brajesh K. , Edwards, Lloyd J. , Huston, John, Meschia, James F., Brott, Thomas G. , Howard, George , Mena-Hurtado, Carlos I., Heck, D , Sangha, Navdeep , Lanzino, Giuseppe, Sharafuddin, Mel, Jumani, Shariq, Voeks, Jenifer H. , Zhang, Yu, Slane, Kevin J., Lazar, Ronald M. , Liebeskind, David S., investigators, on behalf of the POSA trial, Meschia, James F. , Huston, John , Liebeskind, David S. , Mena‐Hurtado, Carlos , Edwards, Lloyd J. , Huston, John , Meschia, James F , Mena-Hurtado, Carlos , Lanzino, Giuseppe , Kashyap, Vikram S , Aronow, Herbert D , Sharafuddin, Mel , Jumani, Shariq , Lazar, Ronald M , Liebeskind, David S. , Howard, George , Marshall, Randolph S. , Lanzino, Giuseppe , Kashyap, Vikram S. , Aronow, Herbert D. , Rai, Pranjal , Slane, Kevin

Mayo Clinic

Stroke | January 29, 2026 | Volume: 57 | Issue: 4 | Pages: 992-999

10.1161/strokeaha.125.054149 | PMID 41608800 Get It

BACKGROUND: Cerebral hemodynamic impairment in patients with asymptomatic high-grade (>70%) internal carotid artery (ICA) stenosis is associated with risk of stroke and cognitive decline, but correlations between the degree of stenosis and hemodynamic impairment are derived from small case series. Using baseline data from 242 participants in the CREST-H study (Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis–Hemodynamics), we hypothesized that the degree of stenosis in the ICA would correlate with time-to-peak (TTP) delay in ipsilateral cerebral blood flow using MR/CT perfusion scans, adjusting for demographic and cardiovascular risk variables. METHODS: From all participants, ICAs were insonated using a 7 to 10 MHz probe for peak systolic velocity (PSV) and end diastolic velocity. Dynamic contrast perfusion imaging was standardized across 61 CREST-H sites, using standard sequential T2*-weighted perfusion imaging. CT perfusion used standard clinical protocols. TTP delay was calculated in the ipsilateral versus contralateral hemispheres. In cross-sectional analysis, linear regression was used to model TTP delay as the outcome variable and PSV, end diastolic velocity, and PSV ICA/common carotid artery ratio on the index and nonindex side as primary predictor variables in 6 separate models, adjusting for covariates, followed by automated backward elimination model reduction. RESULTS: Among 392 CREST-H participants, the 242 with complete data for all variables were included in the regression analysis (age, 70±7.6; 62% M). End diastolic velocity on the index side correlated with TTP delay (β=0.003, P =0.005). PSV had a similar correlation but did not reach significance (β=0.001, P =0.099), nor did ICA/common carotid artery ratio (β=0.003, P =0.126). Nonindex side PSV, end diastolic velocity, and ICA/common carotid artery ratio showed no correlation with TTP delay ( P =0.268, P =0.495, P =0.380, respectively). Circle of Willis completeness did not correlate with TTP. CONCLUSIONS: In this large cohort of patients with high-grade asymptomatic carotid stenosis, higher end-diastolic flow velocities correlated with greater TTP delays, supporting a definition of hemodynamically significant stenosis. Our findings have implications for the management of asymptomatic carotid stenosis, which will be tested in the CREST-H study. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03121209.
Development and Validation of an Optical Sensor-Based Automated Urine Flow Meter for Real-Time Patient Monitoring
Hota, Piyush , Pandian, Adithya Shyamala , Domínguez, Rodrigo E., Mo, Manni , Fu, Bo , Miranda, Sandra, Cay-Durgun, Pinar , Sirganagari, Dheeraj, Serhan, Michael , Serhan, Peter , Karam, Kevin Abi , Gades, Naomi M. , Wiktor, Peter , Thomas, Leslie F. , Lind, Mary Laura , Forzani, Erica , Domínguez, R. , Dominguez, Rodrigo E , Thomas, Leslie , Miranda, Sandra, Sirganagari, Dheeraj Reddy

Mayo Clinic

Sensors | January 28, 2026 | Volume: 26 | Issue: 3 | Pages: 849

10.3390/s26030849 | PMID 41682367 Get It

Acute kidney injury (AKI) affects thousands of hospitalized patients annually, yet early detection remains challenging as serum creatinine elevation lags behind clinical deterioration. Decreased urine output (UO) represents a key diagnostic criterion of AKI, sometimes manifesting hours before biochemical changes; however, current manual monitoring methods are labor-intensive and prone to error. Here, we developed and validated a simple, cost-effective automated urine flow meter using non-contact optical sensors, a peristaltic pump, and microcontroller-based automation for precise, real-time monitoring of urine output in clinical settings, named P-meter. Three successive prototypes (V1, V2, V3) were validated against gold-standard gravimetric measurements over 285 h of testing during animal experiments that required bladder catheterization. Iterative refinement addressed miniaturization challenges, fluid dynamics optimization, and sensor positioning to achieve progressively improved accuracy. The optimized V3 prototype demonstrated further enhanced volumetric precision, stability, and flow accuracy with near-unity linearity vs. reference method (R2 = 0.9889), minimal bias (mean error −0.1 mL), and 94.18% agreement within confidence limits (n = 86), outperforming the initial V1 prototype (R2 = 0.9971, mean error −1.69 mL, n = 207) and intermediate V2 design (R2 = 0.9941, mean error 3.63 mL, n = 390), primarily in terms of reduced bias and improved agreement. The P-meter offers accurate urine output monitoring at a lower cost than commercial systems, facilitating its use in early AKI detection and thereby improving patient outcomes.
DNA copy number patterns reveal prognostic markers and elucidate mechanisms of evolution in IDH-mutant astrocytoma
Drucker, Kristen , Panda, Arijit , Decker, Paul A, Kosel, Matt, Zadeh, Gelareh, Giannini, C., Raghunathan, Aditya, Kizilbash, S., Eckel-Passow, Jeanette E, Jenkins, Robert B, Kizilbash, Sani H. , Drucker, Kristen L , Kosel, Matt L, Kollmeyer, Thomas M. , Maqbool, Muhammad Asad , Šuvakov, Milovan , Vaubel, Rachael A , Raghunathan, Aditya , Kizilbash, Sani H , Abyzov, Alexej , Decker, Paul A. , Kosel, Matthew , Burns, Terry C. , Shafqat, Shameel , Šuvakov, Milovan , Zadeh, Gelareh , Vaubel, Rachael A. , Raghunathan, Aditya , Parney, Ian F. , Ida, Cristiane M. , Abyzov, Alexej , Lachance, Daniel Honore , Eckel‐Passow, Jeanette E.

Mayo Clinic

Neuro-Oncology | January 28, 2026 | Volume: 28 | Issue: 6 | Pages: 1397-1409

10.1093/neuonc/noag019 | PMID 41761580 Get It

Abstract Background Current literature suggestsisocitrate dehydrogenase (IDH)-mutant astrocytoma contains several molecular subgroups. In this study, we are interested in determining the connection between different molecular subgroups with grade and/or survival. Methods A cohort of 470 Mayo Clinic adult patients (≥18 years, 56.2% male) with primary IDH-mutant astrocytoma diagnosed by World Health Organization (WHO) 2021 criteria were examined. Results were validated in an independent cohort of 614 Mayo Clinic Neuropathology consult patients and 235 The Cancer Genome Atlas (TCGA) patients. Results The Mayo Clinic Practice cohort confirmed the association of CDKN2A/B deletion with overall survival (OS, homozygous vs hemizygous vs intact, 2.7 vs 9.6 vs 17.2 years, P &lt; .001). Phosphatase and tensin homolog (PTEN) deletion was also associated with poor OS (7.3 vs 17.4 years, P &lt; .001). Increased number of copy number alterations was associated with OS (continuous variable, HR = 1.027, P &lt; .001). Carrying one or more copies of the germline risk allele at rs55705857 was associated with earlier age of onset (median age 33 vs 35 years, P = .01), and a shorter OS after adjusting for age, grade, sex and treatment (HR = 1.81, P = .007). The Mayo Clinic Neuropathology Consult cohort and TCGA were utilized to validate age of onset and survival, respectively. Unsupervised clustering of the copy number alterations identified several clinically significant groups that may define pathways to disease progression. Losses of chromosomes 11p, 13q, 1p, and 10q were all associated with reduced overall survival in the Mayo Clinic cohort. Conclusions Patients with hemizygous loss of CDKN2A/B, loss of PTEN, increased number of copy number alterations, specific chromosomal arm losses or rs55705857 germline risk allele have reduced overall survival.
Chimerism and a framework for clinical practice: A report from the Cellular Therapies Section Coordinating Committee ( CTSCC ) of Association for Advancement of Blood and Biotherapies (
Guleria, Indira , Connelly‐Smith, Laura , Bapat, Asawari , Klein, Monica, Jacob, Eapen K., Mahanta, Simran, Cui, Wanxing, Reich‐Slotky, Ronit , Spitzer, Thomas R. , Connelly-Smith, Laura , Bapat, Asawari, Alkhateeb, Hassan B. , Anandappa, Annabelle J. , Cui, Wanxing , Celluzzi, Christina M.

Mayo Clinic

Transfusion | January 28, 2026 | Volume: 66 | Issue: 8 | Pages: 1624-1644

10.1111/trf.70095 | PMID 41603138 Get It

Adrenal histologic and genetic characteristics of primary aldosteronism in late adulthood
Blinder, Amy, Sapiro, Dina R., Baker, Jessica , Qin, Zhaoping , Bancos, Irina, Lyden, Melanie L. , Young, W F, Wachtel, Heather , Cohen, D., Kürzinger, Lydia, Fassnacht, Martin, Reincke, Martin, Else, Tobias , Rainey, W E, Nanba, Kazutaka , Bancos, Irina , Fassnacht, Martin , Williams, Tracy Ann , Reincke, Martin , Else, Tobias , Udager, Aaron M , Nanba, Kazutaka , Bancos, Irina , Cohen, Debbie L. , Faßnacht, Martin , Luther, James Matthew , Williams, Tracy Ann , Reincke, Martín , Turcu, Adina F. , Giordano, Thomas J.

Mayo Clinic

European Journal of Endocrinology | January 27, 2026 | Volume: 194 | Issue: 2 | Pages: 208-216

10.1093/ejendo/lvag022 | PMID 41618603 Get It

Abstract Objective Recent studies suggest a unique disease profile in elderly patients with primary aldosteronism (PA), who have a high prevalence of comorbidities and low clinical cure rate post-adrenalectomy. This study aims to investigate histopathology and genetic characteristics of PA in late adulthood. Methods Formalin-fixed, paraffin-embedded adrenal tissue sections from 114 patients with PA who underwent unilateral adrenalectomy at age 60 or older were used. Aldosterone synthase (CYP11B2) immunohistochemistry (IHC) was performed for histopathologic analysis. Somatic DNA variants were identified in aldosterone-producing tissue following CYP11B2 IHC-guided sequencing. Results Histopathologic analysis revealed that 56 adrenals contained an aldosterone-producing nodule (APN) (49%), 44 contained an aldosterone-producing adenoma (APA) (39%), 7 contained multiple APN (6%), and 7 contained only non-functioning adenomas [NFA, of which 6 had at least one aldosterone-producing micronodule (APM) in the adjacent tissue] (6%). NFAs were also identified alongside APN/APA in 24 cases. An APN was the most common histologic subtype in men (51/88, 58%), while APA was predominant in women (18/26, 69%). Of 67 APNs with successful sequencing, the majority had variants in CACNA1D (40/67, 60%). KCNJ5 variants were the most common alteration in APA (14/44, 32%). Conclusions Older individuals with lateralized PA exhibit distinct genetic and histologic causes of disease with sex differences in mutation prevalence and adrenal histopathology. In APN, the most frequently altered gene is CACNA1D, while KCNJ5 variants are most common in APA. Unlike young patients with PA, the presence of NFA is a frequent observation in late adulthood individuals with PA.
Distinct Tau PET Dynamics in Early vs. Late Age-of-Onset Alzheimer’s disease
Chiotis, Konstantinos, Soleimani-Meigooni, David N, Aisen, Paul S, Amuiri, Alinda, Atri, Alireza, Beckett, Laurel, Brickhouse, Michael , Clark, David G, Dage, Jeffrey L, Day, Gregory S, Duara, Ranjan, Eloyan, Ani , Foroud, Tatiana, Graff-Radford, Neill R, Grant, Ian M, Hammers, Dustin B, Honig, Lawrence S, Johnson, Erik C. B., Jones, D. Richard, Kirby, Kala, Koeppe, Robert, Kramer, Joel H, Kukull, Walter A, Leuzy, Antoine , Masdeu, Joseph C., Mendez, Mario F., Musiek, Erik, Nudelman, Kelly N., Onyike, Chiadi U., Riddle, Meghan, Rocha, Salma, Rogalski, Emily, Salloway, Stephen, Schonhaut, Daniel R., Sha, Sharon, Shankar, Ranjani, Taurone, Alexander, Thangarajah, Maryanne, Toga, Arthur W., Touroutoglou, Alexandra, Turner, Raymond Scott, Vemuri, Prashanthi, Wingo, Thomas S., Wolk, David A., Womack, Kyle, Zhang, J. , Carrillo, Maria C., Dickerson, Bradford C., Apostolova, Liana G., Joie, Renaud La, Rabinovici, Gil D., Chiotis, Konstantinos , Blazhenets, Ganna , Soleimani‐Meigooni, David N. , Aisen, Paul , Atri, Alireza , Beckett, Laurel , Clark, David G., Dage, Jeffrey L. , Day, Gregory S. , Duara, Ranjan , Foroud, Tatiana , Graff‐Radford, Neill R. , Hammers, Dustin B , Honig, Lawrence S. , Johnson, Erik C. B. , Jones, David T. , Koeppe, Robert A. , Kramer, Joel H. , Kukull, Walter A. , Lagarde, Julien , Maiti, Piyush , Masdeu, Joseph C , Mendez, Mario F. , Musiek, Erik , Nudelman, Kelly , Onyike, Chiadi U. , Riddle, Meghan , Rogalskı, Emily , Salloway, Stephen, Schonhaut, Daniel R. , Sha, Sharon J. , Shankar, Ranjani , Taurone, Alexander, Thangarajah, Maryanne, Toga, Arthur W. , Touroutoglou, Alexandra , Turner, Raymond Scott , Vemuri, Prashanthi , Wingo, Thomas S , Wolk, David A. , Womack, Kyle , Carrillo, María C. , Dickerson, Bradford Clark , Apostolova, Liana G. , Joie, Renaud La , Rabinovici, Gil D.

Mayo Clinic

No container title available | January 26, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.01.25.26344738 | PMID 41646765 Get It

Abstract Early-onset Alzheimer’s disease (EOAD) and Late-onset AD (LOAD) differ in clinical presentations and rates of progression. We aimed to compare baseline and longitudinal tau PET burden, and their relationship with clinical variables in amyloid-PET positive, cognitively impaired participants from the Longitudinal Early-Onset Alzheimer’s Disease Study (EOAD; n=390) and Alzheimer’s Disease Neuroimaging Initiative (LOAD; n=211). Patients with EOAD showed higher baseline tau PET retention, broader neuroanatomical involvement and faster accumulation rates over time compared to LOAD, after adjusting for amyloid load and clinical stage. Tau PET showed stronger correlations with baseline amyloid burden and clinical measures of global cognition and function in EOAD than LOAD. We conclude that earlier age of onset in AD is linked to a more aggressive tauopathy, which in turn is a primary driver of clinical decline. These findings suggest that optimal therapeutic targets and strategies may differ between EOAD and LOAD. One Sentence Summary Younger patients with Alzheimer’s disease show more aggressive tau spread, suggesting age of onset defines distinct disease pathways with key clinical implications.